Cell plasticity represents the ability of cells to be reprogrammed and to change their fate and
identity, enabling homeostasis restoration and tissue regeneration following damage. Cell …

Anticancer agents continue to dominate the list of newly approved drugs, approximately half
of which are immunotherapies. This trend illustrates the considerable promise of cancer …

Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined
by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A,-N, and-P …

Tissues are dynamically shaped by bidirectional communication between resident cells and
the extracellular matrix (ECM) through cell-matrix interactions and ECM remodelling …

Cancer cell identity and plasticity are required in transition states, such as epithelial–
mesenchymal transition (EMT) and mesenchymal–epithelial transition (MET), in primary …

Breast cancer is one of the most common malignancies among women throughout the world
and is the major cause of most cancer-related deaths. Several explanations account for the …

Metastasis is the major driver of death in patients with cancer. Invasion of surrounding
tissues and metastasis have been proposed to initiate following loss of the intercellular …

The emergence of immunotherapy has been an astounding breakthrough in cancer
treatments. In particular, immune checkpoint inhibitors, targeting PD-1 and CTLA-4, have …

Lung cancer is a major global health problem, as it is the leading cause of cancer-related
deaths worldwide. Major advances in the identification of key mutational alterations have led …

Infiltration of macrophages in solid tumours is associated with poor prognosis and correlates
with chemotherapy resistance in most cancers. In mouse models of cancer, macrophages …